Introduction Lutetium‐177‐PSMA (LuPSMA) is a targeted systemic radioligand treatment for metastatic castration‐resistant prostate cancer (mCRPC). LuPSMA is considered as an experimental treatment not yet used in routine practice. Here, we report our experience following the introduction of LuPSMA therapy at our institution. Methods Referred mCRPC patients were assessed for treatment suitability including Gallium‐68‐PSMA PET/CT and blood tests. Suitable patients underwent up to four cycles of LuPSMA treatment. Response to treatment was assessed by changes in serum prostate‐specific antigen (PSA) levels. Toxicity was assessed by recording of adverse events. Results In an 18 month period, 50 patients underwent 132 cycles of LuPSMA therapy. Patients underwent a median of three cycles each (range: 1–4) and the mean administered amount of activity per cycle was 5.9 GBq (range: 3.5–8.2 GBq). PSA decline could be calculated for 49 patients, with a best PSA decline of ≥ 50% observed in 22 patients (44.9%). Adverse events were reported across 45 of 132 LuPSMA cycles. Most adverse events were grade I (42/45) and the remaining three events were grade II. Conclusion Initial experience at our site supports the use of LuPSMA as an emerging safe and effective treatment for mCRPC. Since introducing LuPSMA therapy at our institution, 44.9% of patients have experienced a decline in PSA level ≥ 50% with low or minimal toxicity. This is an important finding as these patients had previously exhausted all available treatment options. Overall, we have found patients and their primary care doctors have eagerly accepted LuPSMA as another line of defence against mCRPC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.